Raymond James Chief Economist on Cabot: "Must-Have"

 
Jeffrey D. Saut, Senior Vice President and Chief Economist at Raymond James & Associates, quoted Cabot Top Ten Trader’s market view in his September 23, 2015 “Morning Tack." Here’s an excerpt:

Raymond James Morning Tack: “Sage Advice from the Cabot Letter”

By Jeffrey D. Saut, Senior Vice President and Chief Economist, Raymond James

"The next few days will be telling—if the indexes can advance from here, we could receive an intermediate-term buy signal late this week, which will have us loosening the wallet a bit. But if the sellers show up again, all bets are off."—Cabot Top Ten Trader (9-21-15)

On Monday, the insightful Cabot letter stated, "It's been four weeks since the August 24th panic low and the market has done a decent job hanging in there—all of the major indexes probed higher into last week before selling off on Friday. Currently, the major trends of the market remain down, so we're staying defensive. However, the next few days will be telling—if the indexes can advance from here, we could receive an intermediate-term buy signal late this week, which will have us loosening the wallet a bit. But if the sellers show up again, all bets are off. For now, it's best not to anticipate anything."

Plainly, we agree with the stance of "Not to anticipate anything"! Typically, I am not at a loss as to the near-/intermediate-/long-term trend of the equity markets. But, the Dow Theory "sell signal" of August 25th is a head-scratcher for me. Yes, the Dow Dive was a 5 standard deviation event like that of the "flash crash" on May 6, 2010, but as they say, "A sell signal, is a sell signal, is a sell signal." So, we are in total agreement with the must-have Cabot letter. …

Follow this link to your Raymond James "Must Have" special offer:

Mike Cintolo, Cabot Top Ten Trader

This offer is for new subscribers only.
For more information, please call (800) 326-8826 or send us an email.


More Cabot in the News 
Sign up for free Cabot Wealth Advisory e-newsletter


Stock Picks

Loews Corp.

This undervalued stock has strong future earnings growth expectations.

Biogen

Biogen is the market-share leader in treating multiple sclerosis.

Weibo

One of Paul Godwin’s favorite stocks in his Cabot Emerging Markets Investor portfolio.

Cabot Wealth Advisory

Does Alibaba (BABA) Stock Measure Up to Amazon (AMZN)?

By Paul Goodwin on September 23, 2016

Alibaba (BABA) is the Amazon (AMZN) of China. But does BABA stock measure up to AMZN stock? Let’s break it down!Read More >

As Stock Market Trends Change, Invest in these New Leaders

By Michael Cintolo on September 22, 2016

History tells us that all stock market trends change, and if you don’t recognize the leaders of that change early, you risk missing out on the next big winners.Read More >

AMZN Stock vs. FB Stock: Which Is the Better Value Buy?

By J. Royden Ward on September 20, 2016

For the past five years, AMZN stock and FB stock have been two of the market's great growth stories. But could you make the case that either stock is still undervalued? Let’s break it down.Read More >